Literature DB >> 23287962

Is the assessment of the central skeleton sufficient for osseous staging in breast cancer patients? A retrospective approach using bone scans.

Julia Krammer1, Dorothee Engel, Andreas Schnitzer, Clemens G Kaiser, Dietmar J Dinter, Joachim Brade, Stefan O Schoenberg, Klaus Wasser.   

Abstract

OBJECTIVE: By analyzing bone scans we aimed to determine whether the assessment of the central skeleton is sufficient for osseous staging in breast cancer patients. This might be of interest for future staging modalities, especially positron emission tomography/computed tomography, usually sparing the peripheral extremities, as well as the skull.
MATERIALS AND METHODS: In this retrospective study, a total of 837 bone scans for initial staging or restaging of breast cancer were included. A total of 291 bone scans in 172 patients were positive for bone metastases. The localization and distribution of the metastases were re-evaluated by two readers in consensus. The extent of the central skeleton involvement was correlated to the incidence of peripheral metastases.
RESULTS: In all 172 patients bone metastases were seen in the central skeleton (including the proximal third of humerus and femur). In 34 patients (19.8 %) peripheral metastases of the extremities (distally of the proximal third of humerus and femur) could be detected. Sixty-four patients (37.2 %) showed metastases of the skull. Summarizing the metastases of the distal extremities and skull, 79 patients (45.9 %) had peripheral metastases. None of the patients showed peripheral metastases without any affliction of the central skeleton. The incidence of peripheral metastases significantly correlated with the extent of central skeleton involvement (p<0.001).
CONCLUSIONS: Regarding bone scans, an isolated metastatic spread to the peripheral skeleton without any manifestation in the central skeleton seems to be the exception. Thus, the assessment of the central skeleton should be sufficient in osseous breast cancer staging and restaging. However, in case of central metastases, additional imaging of the periphery should be considered for staging and restaging.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23287962     DOI: 10.1007/s00256-012-1562-7

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  26 in total

1.  Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.

Authors:  Dominique Delbeke; R Edward Coleman; Milton J Guiberteau; Manuel L Brown; Henry D Royal; Barry A Siegel; David W Townsend; Lincoln L Berland; J Anthony Parker; Karl Hubner; Michael G Stabin; George Zubal; Marc Kachelriess; Valerie Cronin; Scott Holbrook
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

2.  Bone secondaries in breast cancer: the solitary metastasis.

Authors:  D I Boxer; C E Todd; R Coleman; I Fogelman
Journal:  J Nucl Med       Date:  1989-08       Impact factor: 10.057

3.  Skeletal metastases and mammary cancer.

Authors:  C S Galasko
Journal:  Ann R Coll Surg Engl       Date:  1972-01       Impact factor: 1.891

4.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

Review 5.  Bone scintigraphy screening in stage I-II breast cancer: is it cost-effective?

Authors:  K A Wikenheiser; E B Silberstein
Journal:  Cleve Clin J Med       Date:  1996 Jan-Feb       Impact factor: 2.321

Review 6.  Bone imaging in metastatic breast cancer.

Authors:  Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.

Authors:  Yong Du; Ian Cullum; Tim M Illidge; Peter J Ell
Journal:  J Clin Oncol       Date:  2007-06-25       Impact factor: 44.544

Review 8.  Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.

Authors:  Colleen M Costelloe; Eric M Rohren; John E Madewell; Tsuyoshi Hamaoka; Richard L Theriault; Tse-Kuan Yu; Valerae O Lewis; Jingfei Ma; R Jason Stafford; Ana M Tari; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316

9.  Value of routine 99mTc-MDP bone scintigraphy in the detection of occult skeletal metastases in women with primary breast cancer.

Authors:  C H Yip; M Paramsothy
Journal:  Breast       Date:  1999-10       Impact factor: 4.380

10.  Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Authors:  Till A Heusner; Sherko Kuemmel; Steffen Hahn; Angela Koeninger; Friedrich Otterbach; Monia E Hamami; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-05       Impact factor: 9.236

View more
  1 in total

Review 1.  Fear of impending fractures: when to refer? A case-based review.

Authors:  Caroline Kronisch; Federico Balagué; Jean Dudler
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.